Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8655610 | 0.85 | CYP2C9 (0.38) | LTA4HDYRK1AFGFR1NAMPTPRKCI | |
| SCHEMBL29593970 | 0.83 | FGFR1 (0.53) | LTA4HDYRK1ANFATC1GSK3BFGFR1 | |
| SCHEMBL256337 | 0.83 | FGFR1 (0.53) | LTA4HDYRK1ANFATC1GSK3BFGFR1 | |
| SCHEMBL13083686 | 0.77 | FGFR1 (0.42) | LTA4HFGFR1MAPTJAK2JAK3 | |
| SCHEMBL7020729 | 0.75 | FGFR1 (0.41) | LTA4HFGFR1MAPTJAK2JAK3 | |
| SCHEMBL7975287 | 0.75 | LTA4H (0.48) | LTA4HFGFR1ALDH1A1KDM4EGAA | |
| SCHEMBL1106468 | 0.75 | NFATC1 (0.45) | LTA4HDYRK1ANFATC1GSK3BFGFR1 | |
| SCHEMBL10280661 | 0.75 | MAPK13 (0.39) | LTA4HFGFR1ALDH1A1KDM4EGAA | |
| SCHEMBL1236777 | 0.73 | L3MBTL1 (0.49) | ALDH1A1KDM4E | |
| SCHEMBL559450 | 0.72 | LTA4H (0.49) | LTA4HALDH1A1KDM4ETSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | claimed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | claimed |
| US-5019571-A | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1991-05-28 | — | — | US | claimed |
| EP-4567038-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-06-11 | — | — | EP | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | GENENTECH, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| EP-0946202-B1 | CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2003-09-10 | — | — | EP | disclosed |
| US-6051207-A | PHOSPHATIDYLSERINE LINKED ISOXAZOLE SULFONAMIDE DERIVATIVES; DIAGNOSING AND IMAGING CARDIOVASCULAR DISORDERS | NYCOMED IMAGING AS (NO) | 2000-04-18 | — | — | US | disclosed |
| EP-0272061-A2 | Crystalline cephalosporin antibiotic salts and solvates | ELI LILLY AND COMPANY (US) | 1988-06-22 | — | — | EP | disclosed |
| US-4748172-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| US-4734408-A | PURITY | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4692443-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0138552-A2 | Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | PIK3CA, PIK3CD, PIK3CB | LTA4H 3486/4885DYRK1A 1574/4885NFATC1 1129/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | LTA4H 871/4885DYRK1A 4009/4885NFATC1 321/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | LTA4H 18/4885DYRK1A 2204/4885NFATC1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.